Jones et al. demonstrated that HDAC inhibition with vorinostat, coupled with proteasome inhibition with bortezomib preceded by surgical procedure, was a viable treatment strategy after performing a phase I study with 21 NSCLC patients [79]. This evidence concerns the gene HDAC9 and non-small cell lung carcinoma.